WebDisclosure WebDisclosure
Basculer en Français
9904 Companies
199533 Keywords
130386 Articles
106040 Press releases
Headlines Articles Press releases Harvard Eye Associates Remove
  1. Home
  2. Companies
  3. Harvard Eye Associates
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 02/20/2024 at 17:00, 2 years ago

    Nouveau traitement révolutionnaire contre le glaucome : l'iDose® TR s'installe chez Harvard Eye Associates

    FDA IDose® TR Glaucoma Harvard Eye Associates Thérapie Oculaire
  • BRIEF

    published on 02/20/2024 at 17:00, 2 years ago

    New Revolutionary Treatment for Glaucoma: iDose® TR is Now Available at Harvard Eye Associates

    FDA IDose® TR Glaucoma Harvard Eye Associates Eye Therapy
  • PRESS RELEASE

    published on 02/20/2024 at 17:00, 2 years ago

    Harvard Eye Associates Now Offering iDose(R) TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma

    Harvard Eye Associates introduces iDose® TR, a new FDA-approved treatment for glaucoma and ocular hypertension that provides long-duration drug therapy inside the eye. Dr. Teymoorian leads inaugural treatments at Alicia Surgery Center
    IDose® TR Glaucoma Harvard Eye Associates Ocular Hypertension Travoprost Implant
    Logo of Harvard Eye Associates
Accesswire
  • Published on 02/20/2026 at 18:30, 12 minutes ago

    Sparta Updates Delay in Filing Annual Financial Statements

  • Published on 02/20/2026 at 15:45, 2 hours 57 minutes ago

    Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway

  • Published on 02/20/2026 at 14:30, 4 hours 12 minutes ago

    Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant

  • Published on 02/20/2026 at 14:08, 4 hours 34 minutes ago

    Datavault AI Announces Anticipated Launch of Josh Gibson Stablecoin and Josh Gibson NIL Strategies for Its Forthcoming NIL Exchange

  • Published on 02/20/2026 at 14:00, 4 hours 42 minutes ago

    Nextech3D.ai's Eventdex Platform Powers AI Matchmaking for the SBA's CT Business Matchmaker Event Featuring Government Agencies and Major Prime Contractors

View all ACCESSWIRE
EQS Group
  • Published on 02/20/2026 at 18:36, 5 minutes ago

    EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share

  • Published on 02/20/2026 at 18:31, 11 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 02/20/2026 at 18:23, 19 minutes ago

    POS-Transaction in Own Shares

  • Published on 02/20/2026 at 18:00, 42 minutes ago

    Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme

  • Published on 02/20/2026 at 18:00, 42 minutes ago

    Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS
Les Echos
  • Published on 02/20/2026 at 18:00, 42 minutes ago

    TERACT - Termination of liquidity agreement

  • Published on 02/20/2026 at 18:00, 42 minutes ago

    TERACT - Résiliation du contrat de liquidité

  • Published on 02/20/2026 at 17:35, 1 hour 7 minutes ago

    CHIFFRE D'AFFAIRES 2025

  • Published on 02/20/2026 at 09:28, 9 hours 14 minutes ago

    Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 janvier 2026

  • Published on 02/20/2026 at 09:28, 9 hours 14 minutes ago

    Statement about the number of shares composing the share capital and the number of voting rights as of January 31, 2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy